A carregar...

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma

Multiple Myeloma (MM) is a haematologic malignancy characterized by the accumulation of clonal plasma cells in the bone marrow. Over the last 10–15 y the introduction of the proteasome-inhibitor bortezomib has improved MM prognosis, however relapse due to bortezomib-resistance is inevitable and the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Cycle
Main Authors: Murray, Megan Y, Zaitseva, Lyubov, Auger, Martin J, Craig, Jenny IO, MacEwan, David J, Rushworth, Stuart A, Bowles, Kristian M
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4613153/
https://ncbi.nlm.nih.gov/pubmed/25565020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2014.998067
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!